Botulinum toxin injection may ward off postop AFib

Injecting botulinum toxin injection into the epicardial fat pads prevented recurrences of atrial tachyarrhythmia in the postoperative period in patients with prior paroxysmal atrial fibrillation undergoing coronary artery bypass grafting surgery, according to results of a study. » Full article

Investigational drug has potential to be first DMARD for knee OA

With global disability concerns rising, Voltarra Pharmaceuticals, Inc. and Menzies Research Institute at the University of Tasmania in Hobart, Australia, have initiated a phase 3, randomized multicenter clinical trial to assess the efficacy and safety of VOLT01 for controlling knee osteoarthritis. » Full article

Continuing Education

MTM essentials for hypertension—Part 2: Drug therapy considerations

This month's article is the fourth in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss place in therapy of drug classes used to treat hypertension and review drug considerations of prescription antihypertensive medication and herbal supplements that are relevant to medication therapy management of hypertension.

To read and print the article with TEST QUESTIONS, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

• Warfarin may benefit Afib patients with CKD after heart attack

• OA treatment for knee pain approved by FDA

RESOURCES

Latest Clinical News

FDA approves new IV antibacterial drug used to treat adults with skin infections

FDA has approved dalbavancin (Dalvance, Durata Therapeutics) for injection for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
» Full article